NASDAQ · Biotechnology

QNCX (QNCX) Stock

$17.85 -0.03% NASDAQ: QNCX Healthcare

Valuation

MetricValue
Price$17.85
Market Cap$4.97M
P/E Ratio-0.05
P/B Ratio0.82
P/S Ratio0.00
EPS (TTM)$-16.80
52-Week High$45.50
52-Week Low$0.79
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-192.90%
ROA-45.44%
ROCE142.86%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.03
Current Ratio0.53

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-90.0M$-52.0M$-35.0M$-57.0M$-50.0M
Net Profit$-90.0M$-52.0M$-31.0M$-57.0M$-84.0M
EPS$-30.30$-15.40$-8.40$-13.10$-16.80
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$133.0M$104.0M$180.0M$114.0M$94.0M
Total Liabilities$15.0M$3.0M$95.0M$84.0M$129.0M
Cash$70.0M$45.0M$21.0M$6.0M$6.0M
Borrowings$1.0M$0$14.0M$15.0M$18.0M

Latest News

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board GlobeNewswire · Jun 30, 2026 Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy Insider Monkey · Jun 2, 2026 UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD GlobeNewswire · May 18, 2026 Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD GlobeNewswire · May 18, 2026 Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-63.0M$-44.0M$-18.0M$-32.0M$-41.0M
Investing Cash Flow$59.0M$18.0M$-6.0M$22.0M$23.0M
Financing Cash Flow$0$0$0$-5.0M$0
Net Cash Flow$3.0M$-25.0M$-24.0M$-15.0M$0
Free Cash Flow$-63.0M$-44.0M$-18.0M$-32.0M$-42.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA0.05
FCF Yield-770.09%
Quick Ratio2.92
Interest Coverage—
Return 1Y-94.63%
Return 3Y-94.30%
Return 5Y-99.83%

Ownership

Insiders Held0.32%
Institutions Held14.20%
Institutions Float Held14.25%
Institutional HolderSharesReport Date
Gen-wealth Partners Inc 1,6512026-03-31
Catalyst Funds Management Pty Ltd1,5002026-03-31
Advisory Services Network, LLC2752026-03-31
Parallel Advisors, LLC402026-03-31
SBI Securities Co., Ltd.72026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADVMAdverum Biotechnologies, Inc. $4.36 +0.00% -0.66 $96.26M 0.00%
ALXO $1.95 -2.26% -1.04 $261.72M 0.00%
ATYR $0.49 +1.19% -0.72 $47.62M 0.00%
CAMP $3.47 +6.12% -1.70 $73.70M 0.00%
CNTB $2.07 -1.67% -2.31 $130.02M 0.00%

About QNCX

QNCX is led by CEO Dirk Thye, employs 36 people, headquartered in US, publicly traded since 2019.

QNCX stock trades at $17.85 with a market capitalization of $4.97M. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of 0.82, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.79 and $45.50, and currently trades 60.8% below its 52-week high.

On profitability, QNCX generates a return on equity (ROE) of -192.90%, return on capital employed of 142.86%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides